Dimension Capital
SelectiveFiled to raiseNew York, NYBiotechnology, Pharmaceuticals, HealthcareLast fund filed 2026
3 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Dimension Capital IIIFiled to raise in 2026, with no closing reported yet. | 2026 | $750M | $0 | 0 |
| Dimension Capital IIFiled to raise in 2024, with no closing reported yet. | 2024 | $500M | $0 | 0 |
| Dimension Capital I | July 2022 | $350M | $350M | 81 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
3 partners are named across this firm’s filings, 3 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Nan Li | Selective | Biotech & pharma | 6 | 2 |
Classified sectors of Dimension Capital’s own portfolio companies, based on 11 with a verified or cited source.
| Firm | Shared boards | Companies |
|---|---|---|
| Obvious Ventures | 6 | AI Fleet, Fiveonefour Labs, Hatfield, ITERATIVE SCOPES, Odyssey Therapeutics, ZY THERAPEUTICS |
| Lux Capital | 4 | 3Scan, Eikon Therapeutics, Kallyope, Variant Bio |
| DCVC | 2 | 3Scan, RECURSION PHARMACEUTICALS |
| Abingworth Bioventures |
| Adam Goulburn | Quiet | Biotech & pharma, Digital health, Enterprise software | 11 | 0 |
| Zavain Dar | Quiet | Biotech & pharma, Manufacturing & industrials | 4 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Dimension Capital’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| 1 |
| Odyssey Therapeutics |
| Biomatics Capital Partners | 1 | Variant Bio |
| Caduceus Capital | 1 | Odyssey Therapeutics |
| Defy | 1 | Hatfield |
| ff Venture Capital | 1 | Authorea |
| Foresite | 1 | Eikon Therapeutics |
| Orbimed Genesis | 1 | Odyssey Therapeutics |
| The Column Group | 1 | Kallyope |
A shared board seat: a company where filings name a Dimension Capital partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.